EntreMed Panzem To Boost Bioavailability Under Elan Supply Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan will reformulate and manufacture Panzem (2-methoxyestradiol) as an oral liquid formulation using its NanoCrystal technology. EntreMed expects to initiate a clinical oncology program in 2005 using the new formulation.